Answers are grounded in this paper and cite their sources.
Cigarette smoking, the major cause of chronic obstructive pulmonary disease (COPD), induces activation of pro-inflammatory pathways in the airway epithelium. Salbutamol, a selective and short-acting ?2-adrenoceptor agonist, is used for bronchospasm relief in patients with asthma and COPD. In addition, salbutamol also presents anti-inflammatory effects. Here, we evaluated whether salbutamol (10-5-10- 7 M) can reduce on bronchial epithelial cells (BEAS-2B cells) the inflammatory parameters induced by cigarette smoke extract (CSE; 1%). After 24h, Salbutamol reduced the IL-1? production induced by CSE in a concentration-response manner. Salbutamol (10-6 M) reduced the IL-8 production and increased the IL-10 production on CSE-stimulated cells. Also, salbutamol (10-6 M) decreased the ICAM-1 expression and the reactive oxygen species production. These anti-inflammatory effects could be associated with the down regulation of activation of NF-?B. Salbutamol may be a potential alternative treatment to airway inflammation caused by cigarette smoking such as in COPD patients.
No takes yet. Share an insight, caveat, or question.
Gouveia et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: